Use of borate-polyol complexes in ophthalmic compositions

• US 6,849,253 B2
• Filed: 11/22/2002
• Issued: 02/01/2005
• Est. Priority Date: 05/06/1992
• Status: Expired due to Fees

• Current Assignee: Alcon Research Limited (Nestle SA)
• Original Assignee: Alcon Manufacturing Limited (Alcon Incorporated)
• Inventors: Dassanayake, Nissanke L., Chowhan, Masood
• Primary Examiner(s): Kunz, Gary
• Assistant Examiner(s): Haghighatian, Mina
• Application Number:
  US10/302,294
• Publication Number:
  US 20030130207A1
• Time in Patent Office: 802 Days
• Field of Search: 424/78.04, 424/427, 424/78.26, 424/659, 514/912, 514/839, 514/840, 514/812, 514/254
• US Class Current: 424/78.04
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: Y10S 134/901 Contact lens

Abstract

Water-soluble borate-polyol complexes are useful as buffers and/or antimicrobials in aqueous ophthalmic compositions, including those containing polyvinyl alcohol. These compositions have greater antimicrobial activity than comparable compositions containing typical borate buffers and unexpectedly increase the antimicrobial efficacy of other antimicrobial agents when used in combination. In addition, use of the borate-polyol complexes avoids the incompatibility problem typically associated with the combination of borate buffer and polyvinyl alcohol; therefore, the compositions disclosed herein may also contain polyvinyl alcohol.

Claims

1. An aqueous ophthalmic solution comprising:

0.5 to 6.0 wt. % of a water soluble borate-polyol complex to enhance the antimicrobial activity of the solution, and water;

wherein the borate-polyol complex comprises a borate compound selected from the group consisting of boric acid and pharmaceutically acceptable salts thereof and propylene glycol, and the molar ratio of borate to polyol is 1;

0.1 to 1;

10.

2. An aqueous ophthalmic solution according to claim 1, wherein the solution further comprises an effective amount of a viscosity-enhancing polymer.

3. An aqueous ophthalmic solution according to claim 2, wherein the viscosity-enhancing polymer comprises a cellulosic polymer.

4. An aqueous ophthalmic solution according to claim 3, wherein the cellulosic polymer comprises hydroxypropyl methylcellulose.

5. An aqueous ophthalmic solution according to claim 1, wherein the solution does not contain an ophthalmically acceptable antimicrobial agent.

6. An aqueous ophthalmic solution according to claim 1, wherein the solution contains the borate-polyol complex in an amount of 1.0 to 2.5 wt. %.

7. An aqueous ophthalmic solution according to claim 6, wherein the molar ratio of borate to polyol is 1:

0.1 to 1;

1.

8. An aqueous ophthalmic solution according to claim 6, wherein the molar ratio of borate to polyol is 1:

0.25 to 1;

2.5.

9. An aqueous ophthalmic solution according to claim 6, wherein the solution does not contain any ophthalmically acceptable antimicrobial agent.

10. An aqueous ophthalmic solution comprising:

0.5 to 6.0 wt. % of a water soluble borate-polyol complex to enhance the antimicrobial activity of the solution, and water;

wherein the borate-polyol complex comprises a borate compound selected from the group consisting of boric acid and pharmaceutically salts thereof and sorbitol, and the molar ratio of borate to polyol is 1;

0.1 to 1;

10.

11. An aqueous ophthalmic solution according to claim 10, wherein the solution further comprises an effective amount of a viscosity-enhancing polymer.

12. An aqueous ophthalmic solution according to claim 11, wherein the viscosity-enhancing polymer comprises a cellulosic polymer.

13. An aqueous ophthalmic solution according to claim 12, wherein the cellulosic polymer comprises hydroxypropyl methylcellulose.

14. An aqueous ophthalmic solution according to claim 10, wherein the solution does not contain an ophthalmically acceptable antimicrobial agent.

15. An aqueous ophthalmic solution according to claim 10, wherein the solution contains the borate-polyol complex in an amount of 1.0 to 2.5 wt. %.

16. An aqueous ophthalmic solution according to claim 15, wherein the molar ratio of borate to polyol is 1:

0.1 to 1;

1.

17. An aqueous ophthalmic composition according to claim 15, wherein the molar ratio of borate to polyol is 1:

0.25 to 1;

2.5.

18. An aqueous ophthalmic solution according to claim 15, wherein the solution does not contain an ophthalmically acceptable antimicrobial agent.